glaucoma

Aqueous angiography: Moving toward individualized IOP control
Aqueous angiography: Moving toward individualized IOP controlAqueous angiography facilitates increased understanding of aqueous humor outflow that can provide individualized treatment for IOP control.
ARMOR surveillance study update gives current insights on antibiotic resistance for clinical ocular isolatesThe most recent analyses of data from the ARMOR (Antibiotic Resistance Monitoring in Ocular micRoorganisms) Surveillance Program can guide clinicians choosing antibiotic therapy for initial empiric therapy and infection prophylaxis. The information also reinforces the importance of prudent antibiotic prescribing to limit the development of bacterial resistance to existing options, according to Penny Asbell, MD.
Glaucoma patients' gender plays a role in treatmentsLouise A. Sclafani, OD, FAAO, talks about the different concerns with men and women when diagnosing and treating glaucoma patients at Vision Expo West in Las Vegas, NV.
Exploring wider role for premium IOL implantation in glaucoma patientsWhen it comes to recommending a premium IOL, a patient’s glaucoma is only one factor to consider. Just like any other patient planning cataract surgery, visual needs and preferences for/against glasses are also important factors.
Medically managing glaucoma
Medically managing glaucomaOptometry Times Editorial Advisory Board member Leo P. Semes, OD, FAAO, sits down to talk about managing glaucoma, treatment recommendations, intraocular pressure, and new medications in treating glaucoma at Vision Expo West in Las Vegas, NV.
Corneal hysteresis indicator for glaucoma progression
Corneal hysteresis indicator for glaucoma progressionJustin Schweitzer, OD, in Sioux Falls, SD, examines corneal hysteresis and discusses how it may be an indicator for glaucoma progression in patients at Vision Expo West in Las Vegas, NV.
How to achieve a calm, stress-free ORAchieving the best visual outcomes in challenging cases is a high priority in surgical retina. However, meeting that goal involves a high level of creativity, especially in complex cases associated with other ocular comorbidities.
Progression of visual field loss not always easy to test, analyzeAssessing visual field progression in glaucoma may be more of an art than a science—and there is no one test to give reliable information that is needed about a patient, said Chris A. Johnson, PhD, DSc, FAAO, FARVO, professor, Department of Ophthalmology, and director, Visual Field Reading Center, University of Iowa, Iowa City.
Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
Fixed-combination glaucoma agent yields positive safety, efficacy dataA phase III trial for the fixed-combination netarsudil/latanoprost agent (Roclatan, Aerie Pharmaceuticals)reports positive results. The company plans to submit a NDA for the drug in early 2018.